MoA Aggressive Allocation Fund earns a High Process Pillar rating. The most important driver of the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm's ...

The deal is notable because the U.K.’s cost-effectiveness watchdog initially raised concerns about the durability of the treatment, called Casgevy, in a preliminary ruling last year, saying it ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Prof Bola Owolabi, of NHS England, called it a "monumental step forward", and said the one-off treatment Casgevy, also known as Exa-cel, "holds a very real prospect of a cure". A confidential ...

It is thought that 1,700 people could be eligible after the National Institute for Health and Care Excellence (Nice) approved Casgevy for certain patients with the genetic condition. NHS officials ...

It is estimated that 1,700 people could be eligible after the National Institute for Health and Care Excellence (Nice) approved Casgevy for certain patients with the genetic condition. NHS officials ...

Only some patients with the disease will be eligible to receive Casgevy. The treatment is designed to work by editing the faulty gene in a patient’s bone marrow stem cells. The cells are taken out of ...

Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing tool Crispr (Alamy/PA) A £1.65 million treatment has been approved for use for some NHS patients ...

The launch of Casgevy, the first gene-editing therapy ever approved, has been slow for sickle cell disease and transfusion-dependent beta thalassemia, the analyst tells investors in a research note.